Johnson & Johnson (NYSE:JNJ) is one of the best pharma stocks to invest in now. Johnson & Johnson (NYSE:JNJ) announced on ...

The biggest names in cardiology tech gathered in New Orleans for the American College of Cardiology (ACC) Scientific Sessions ...

News from ACC 2026 dominates our most-read list, along with the dyslipidemia guidelines, Lp(a) vs CAC, and apixaban for VTE.

Study investigators cautioned against routine use of the device in complex percutaneous coronary interventions and to treat ...

Using a microaxial flow pump prior to and during cardiac stenting procedures for patients with severe heart attacks who don't ...

Two separate randomized trials of Johnson & Johnson’s miniaturized Impella heart pumps failed to illustrate the devices’ ...

Microaxial flow pump circulatory support with the Impella device during percutaneous coronary intervention (PCI) didn't help outcomes for complex patients not in cardiogenic shock, two randomized ...

A Phoenix man survived two cardiac arrests without a heart transplant, and doctors are calling it a miracle. His odds of surviving a transplant were less than 20%.

Using a microaxial flow pump prior to and during cardiac stenting procedures for patients with severe heart attacks who don't have cardiogenic shock does not significantly reduce heart damage.

This screenshot from an Abiomed video demonstrates placement of the Impella 2.5 and Impella CP. Delivered in a minimally invasive way, Impella pumps actively unload the heart, aiding native heart ...

Using a microaxial flow pump prior to and during cardiac stenting procedures for patients with severe heart attacks who don't have cardiogenic shock ...

In the STEMI Door-to-Unload trial, use of Impella missed the mark in patients with anterior MI without cardiogenic shock.